Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1 study of AMG 427 (emirodatamab) in relapsed/refractory AML
jRCT2031210152Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of FLT3-directed BiTE molecule in acute myeloid leukemia (AML), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities (DLTs) and Treatment-emergent adverse events (TEAEs) and treatment-related TEAEs. Started Sep 2018; status: completed.
02
Drugs
FLT3-directed BiTE molecule
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031210152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210152.